Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Evolution Group PLC

15 Dec 2011 12:12

RNS Number : 0651U
BlackRock Group
15 December 2011
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

BlackRock, Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

The Evolution Group PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

14th December 2011

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

Yes, Investec Limited and Investec PLC

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

10,256,166

4.41

(2) Derivatives (other than options):

1,979,665

0.85

(3) Options and agreements to purchase/sell:

TOTAL:

12,235,831

5.26

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

1p ordinary

Sale

9,850

GBP 0.77

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

None.

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None.

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

No

 

 

Date of disclosure:

15 December 2011

Contact name:

Euan Peachey

Telephone number:

020 7743 3917

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETLELFFFLFFFBF
Date   Source Headline
13th Dec 20177:00 amRNSCollaboration with King's College London
11th Dec 20177:15 amRNSHardman Res.: Funded to the end of Phase II trials
8th Dec 20177:15 amRNSPlacing and Notice of General Meeting
8th Dec 20177:00 amRNSInterim Results
23rd Nov 201711:05 amRNSSecond Price Monitoring Extn
23rd Nov 201711:00 amRNSPrice Monitoring Extension
4th Oct 20177:00 amRNSFirst European Patent Grant
31st Aug 20177:00 amRNSIssue of Equity and Total Voting Rights
2nd Aug 20171:00 pmRNSSFX-01 data published in Peer Reviewed Journal
27th Jul 20177:00 amRNSResult of AGM
26th Jul 20177:00 amRNSAGM Statement
11th Jul 201712:30 pmRNSCharity-funded Study of SFX-01 in TNBC
21st Jun 201710:00 amRNSPosting of Annual Report and AGM Notice
21st Jun 20177:15 amRNSHardman Research: Making clinical progress
13th Jun 20177:00 amRNSFull Year Results
1st Jun 20177:00 amRNSCompassionate Use Programme and Trials Update
25th May 20177:00 amRNSNotice of Preliminary Results
3rd Apr 20172:15 pmRNSDirectorate Change
28th Mar 20172:45 pmRNSFurther US Patent Grant
6th Mar 20177:00 amRNSIssue of Equity, PDMR Shareholding and TVR
14th Feb 20171:30 pmRNSPatent Grant in the United States
13th Feb 20177:00 amRNSServices Agreement with APTrans
17th Jan 20177:00 amRNSFirst Patient Dosed in Breast Cancer Trial
17th Jan 20177:00 amRNSAppointment of CFO and Head of Clinical Operations
11th Jan 20177:00 amRNSPositive DSMB Review of SAS Trial
5th Dec 20167:00 amRNSHalf Yearly Report
29th Nov 201611:53 amRNSHardman Research: Clinical sulforaphane potential
17th Nov 20167:00 amRNSNotice of Interim Results
1st Nov 201612:30 pmRNSGrant of Options
15th Sep 20167:00 amRNSUpdate re SFX-01 Data at ECTRIMS 2016
8th Sep 20163:30 pmRNSPresentation of SFX-01 Data at ECTRIMS 2016
24th Aug 20163:15 pmRNSOrphan Designation in the USA in SAH
17th Aug 20167:00 amRNSApproval for Phase II Study in Breast Cancer
24th Jun 20163:36 pmRNSResult of AGM
9th Jun 20167:00 amRNSGrant of Options
2nd Jun 20167:00 amRNSPosting of Annual Report and AGM Notice
31st May 20167:00 amRNSFinal Results
9th May 20167:00 amRNSNotification of Preliminary Results
3rd May 20167:00 amRNSFirst Patient Dosed in Phase II Trial
2nd Mar 20167:00 amRNSApproval of Phase II Clinical Trial in SAH
19th Jan 20163:23 pmRNSCorrection: Director Share Purchases
19th Jan 20167:00 amRNSDirector Share Purchases
11th Jan 20167:00 amRNSExercise of Options
4th Jan 20167:00 amRNSAppoints Chief Medical Officer
7th Dec 20157:00 amRNSHalf Yearly Report
23rd Nov 20157:00 amRNSExpands Pipeline with Novel Compounds
16th Nov 20157:00 amRNSNotification of Half Year Results
23rd Oct 201511:45 amRNSNotification of Major Interest in Shares
21st Oct 20157:00 amRNSFirst Day of Dealings
21st Dec 20114:30 pmRNSTemporary Suspension Evolution Group PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.